Notice2024-05676
Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production Activity; Merck Sharp & Dohme LLC; (Pharmaceutical Products for Research and Development); Rahway, New Jersey
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 18, 2024
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 53 (Monday, March 18, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 53 (Monday, March 18, 2024)]
[Notices]
[Page 19295]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-05676]
[[Page 19295]]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-12-2024]
Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production
Activity; Merck Sharp & Dohme LLC; (Pharmaceutical Products for
Research and Development); Rahway, New Jersey
Merck Sharp & Dohme LLC submitted a notification of proposed
production activity to the FTZ Board (the Board) for its facility in
Rahway, New Jersey, within FTZ 49. The notification conforming to the
requirements of the Board's regulations (15 CFR 400.22) was received on
March 8, 2024.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
The proposed finished products for research and development
include: drug products containing the following active pharmaceutical
ingredients: MK-7962 Sotatercept, MK-3475A monoclonal antibody, MK-2060
monoclonal antibody, MK-6024 Efinopegdutide, and, MK-5475 hypertension;
clinical placebos; and, blinded clinical trial kits (duty rate ranges
from duty-free to 6.5%, and 40 cents/kg+10.4%).
The proposed foreign-status materials and components include:
active pharmaceutical ingredients: MK-5475 Hypertension, MK-6024
Efinopegdutide, MK-7962 Sotatercept, MK-3475A monoclonal antibody, and
MK-2060 monoclonal antibody; syringes and syringe parts: barrels, hubs,
plungers, needles; autoinjectors and autoinjector subassemblies:
casings and dosing mechanisms; and, empty gelatin capsules (duty rate
ranges from duty-free to 6.5%). The request indicates that certain
materials/components are subject to duties under section 301 of the
Trade Act of 1974 (section 301), depending on the country of origin.
The applicable section 301 decisions require subject merchandise to be
admitted to FTZs in privileged foreign status (19 CFR 146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#4523313f0531372421206b222a33"><span class="__cf_email__" data-cfemail="98feece2d8eceaf9fcfdb6fff7ee">[email protected]</span></a>. The closing period for their receipt April 29, 2024.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Diane Finver at
<a href="/cdn-cgi/l/email-protection#26624f47484308604f4850435466525447424308414950"><span class="__cf_email__" data-cfemail="bdf9d4dcd3d893fbd4d3cbd8cffdc9cfdcd9d893dad2cb">[email protected]</span></a>.
Dated: March 12, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-05676 Filed 3-15-24; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 18, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.